awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845
Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845
Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.
P2860
Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3d75e2814d497315429bc2b597a86a41cedd9d92
P2860
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.